Cannabidiol in Canine Drug-Resistant Epilepsy. A Comprehensive Case Study of Jack's Journey

This paper presents a detailed case study of Jack, a canine diagnosed with drug-resistant epilepsy, focusing on the effectiveness of Cannabidiol (CBD) monotherapy as a treatment strategy. Jack exhibited resistance to conventional antiepileptic drugs such as phenobarbital and potassium bromide, prompting the exploration of alternative therapeutic approaches. The study analyzes Jack’s response to CBD administration, dosage adjustments, and its long-term impact on epilepsy management. It also examines potential interactions with the cytochrome P450 enzyme system and the neuroprotective properties of CBD. Key findings suggest that CBD effectively controlled seizure activity in this case, highlighting its potential role as a primary therapeutic option in selected patients. This case study contributes to the growing body of evidence supporting CBD as a viable therapeutic option in the management of refractory canine epilepsy.